MedTrace Logo

Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer

NCT01242631 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-02-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether the drug everolimus is effective in the treatment of patients with relapsed cancer of the testis. This is a phase II study where all patients will receive the study drug (everolimus 10 mg daily). The primary endpoint of the study is the rate of patients that have no progressive disease after 12 weeks of treatment. Twenty-five evaluable patients will be treated in this study.

Conditions

  • Testicular Cancer
  • Germ Cell Cancer

Interventions

DRUG

Everolimus

Everolimus 10 mg orally per day.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Martin H Fenner, MD · Hannover Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01242631 on ClinicalTrials.gov